JYB1907 in Subjects With Advanced Solid Tumors

Inclusion Criteria: 1. Able to provide written informed consent voluntarily; 2. Age ≥18, male or female; 3. Have at least one evaluable lesion (Dose escalation) or measurable lesion; 4. Expected survival ≥12 weeks； 5. Eastern Cooperative Oncology Group (ECOG) performance status ≤2; Exclusion Criteria: 1. Received within 4 weeks before the initial treatment, or scheduled during the study to receive a major surgery, live attenuated vaccines, or any anti-tumor therapy. 2. With severe tumor complications. 3. Pregnant or lactating women, or positive serum pregnancy test; 4. Concurrent participation in another interventional study； 5. With other diseases or clinical abnormalities assessed by the Investigator as ineligible.